Otonomy appoints new chief commercial officer
This article was originally published in Scrip
Executive Summary
Otonomy, a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for diseases and disorders of the inner and middle ear, has named Anthony J Yost chief commercial officer. Most recently Mr Yost was chief commercial officer for specialty pharma companies Prometheus Laboratories and EKR Therapeutics. Prior to this he was general manager for the Western US operating unit of Novartis Pharmaceuticals, where he led commercial operations totaling more than 600 employees generating annual revenues in excess of $600m.